1. Introduction {#s0005}
===============

Nephroblastoma (Wilms\' tumor) is an embryonal kidney malignancy. It is the most commonly diagnosed renal tumor in children, but rarely occurs in adults. The annual incidence rate of nephroblastoma is about 7--10 cases per million in children younger than 15 years old, making up 6--7% of all childhood cancers ([@bb0095]). The incidents vary among the different ethnic groups, with the highest rates found in black Africana and the lowest in Asians ([@bb0095]). The variation in incident rates reflected implication of genetic factors in the aetiology of the disease. It was estimated that nephroblastoma affected 3.3 in one million children between 2002 and 2010 in China ([@bb0005]). Nephroblastoma is highly responsive to treatments, with a relatively favorable prognosis. The long term survival for regional and metastatic disease is over 90% and 75%, respectively ([@bb0095], [@bb0155]). However, there is still room for improvement in risk prediction and management of the disease.

Approximately, 10%--15% of nephroblastomas are related to germline pathogenic variants or epigenetic alterations formed in the early stage of embryogenesis ([@bb0030]). Roughly 1%--2% of cases have at least one relative also developed Wilms\' tumor. Germline genetic and epigenetic variations are most frequently identified in *Wilms*\' *Tumor 1* (*WT1*) gene and the 11p15.5 locus ([@bb0030]) in patients with Wilms\' tumor. In addition, genetic aberrations in other genes, including *VHL*, *PBRM1*, *BAP1*, may be implicated in the tumorigenesis of kidney cancers ([@bb0160]). Although pathogenic genetic alterations are clear in some families, they remain unknown for the majority of individuals. Therefore, additional relevant variants in other genes should be further explored.

BRCA1-associated RING domain protein 1 (BARD1) is encoded by the human *BARD1* gene, which is known to interact with breast cancer susceptibility gene 1 (BRCA1) ([@bb0175], [@bb0080], [@bb0085]). BARD1 shares homologies with BRCA1 in primary structure within the N-terminal RING finger motif and two C-terminal BRCA1 carboxy-terminal (BRCT) domains ([@bb0170]). These two proteins form a heterodimer through their [N-terminal](https://en.wikipedia.org/wiki/N-terminal){#ir0005} [RING finger mofis](https://en.wikipedia.org/wiki/RING_finger_domain){#ir0010} ([@bb0110]). BARD1 is able to regulate the tumor-suppressor function of BRCA1 ([@bb0035], [@bb0090], [@bb0135], [@bb0085]). Disruption of the BARD1/BRCA1 interaction may impair BRCA1 tumor suppression functions. BARD1 itself is also a tumor suppressor ([@bb0085]). Mice with conditional deletion of *BARD1* in mammary epithelial cells developed breast cancer ([@bb0130]). Moreover, structure-affecting mutations in the *BARD1* gene were frequently identified in [breast](https://en.wikipedia.org/wiki/Breast_cancer){#ir0015}, [ovarian](https://en.wikipedia.org/wiki/Ovarian_cancer){#ir0020}, and [uterine cancers](https://en.wikipedia.org/wiki/Uterine_cancer){#ir0025} ([@bb0080]). Because of the biological importance of BARD1, single nucleotide polymorphisms (SNPs) that alter its function or expression may modify susceptibility to cancer. A previous genome-wide association study (GWAS) found that *BARD1* gene polymorphisms (rs7585356 G \> A, rs6435862 T \> G and rs3768716 A \> G) were associated with neuroblastoma susceptibility ([@bb0015]). Given the importance of BARD1 in cancer, we investigated whether the three SNPs confer nephroblastoma susceptibility in a Southern Chinese population consisting of 145 cases and 531 controls.

2. Materials and Methods {#s0010}
========================

2.1. Study Population {#s0015}
---------------------

Totally, 145 patients with nephroblastoma and 531 cancer-free controls were recruited for this hospital-based case-control study. All the cases were enrolled from the Guangzhou Women and Children\'s Medical Center, with newly diagnosed and histopathologically verified neuroblastoma. The cancer-free controls were frequency matched to cases on age and sex, who visited the same hospital for a regular physical examination ([@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0180], [@bb0185]). All the participants were ethnic Chinese Han. Patients would be excluded, if bearing other types of tumor, secondary or recurrent tumors, and receiving chemotherapy or radiotherapy previously. Demographic and clinical data on each participant, including age, sex, and clinical characteristics, were acquired by structured questionnaire or archived medical records. This study obtained approval from the Institutional Review Board of Guangzhou Women and Children\'s Medical Center. Written informed consent was signed by all participants or their guardians in accordance with the Declaration of Helsinki.

2.2. SNP Selection and Genotyping {#s0020}
---------------------------------

Three SNPs (rs7585356 G \> A, rs6435862 T \> G, and rs3768716 A \> G) in the *BARD1* gene identified in a previous GWAS were chosen for this study ([@bb0015]). We used the TIANamp Blood DNA Kit (TianGen Biotech Co. Ltd., Beijing, China) to isolate genomic DNA from 2 mL venous blood sample, following the manufacturer\'s instructions ([@bb0065]). Samples of genomic DNA were processed according to previous protocol ([@bb0050], [@bb0195], [@bb0200]). Generally, we prepared all the DNA samples in a dilution of 10 ng/μL and added to the 96-well plates until further utilization. Genotyping for the SNPs was performed in the 384-well format and Taqman method was adopted. For the purpose of quality control, 10% of samples were picked randomly and regenotyped, and the two sets of genotyping results were 100% concordant.

2.3. Statistical Analysis {#s0025}
-------------------------

*χ*^2^ test was performed to compare the differences in the demographic variables and distributions of genotypes between cases and controls. We used goodness-of-fit *χ*^2^ test to evaluate whether genotype distributions of SNPs followed Hardy-Weinberg equilibrium (HWE) in control subjects. Unconditional univariate logistic regression analysis was performed. Furthermore, odds ratios (ORs) and 95% confidence intervals (CIs), with adjustment for age and sex, were computed to determine the strength of the associations between studied SNPs and the risk of nephroblastoma. We also performed false-positive report probability (FPRP) analysis to further explore if the significant findings were just chance or noteworthy observations ([@bb0055]). SAS software (version 9.1; SAS Institute, Cary, NC) was used to conduct all statistical analyses. All *P* values were two-sided, and a significance level of 0.05 was adopted for this study.

3. Results {#s0030}
==========

3.1. Characteristics of Study Population {#s0035}
----------------------------------------

We totally recruited 145 nephroblastoma patients and 531 cancer-free controls with ages ranging from 1 to132 and from 0.07 to 156 months old, respectively ([Table 1](#t0005){ref-type="table"}). There were no significant difference between cases and controls regarding age (26.17 ± 21.48 vs. 29.73 ± 24.86 months old, *P* = 0.725) and sex (*P* = 0.956). The clinical stages were also obtained for nephroblastoma patients. There were 4 patients (2.76%) in stage I, 49 (33.49%) in stage II, 50 (34.48%) in stage III, and 33 (22.76%) in stage IV. We failed to determine clinical stage for 9 patients.Table 1Frequency distribution of selected variables for nephroblastoma cases and cancer-free controls.Table 1VariablesCases (n = 145)Controls (n = 531)*P*[a](#tf0005){ref-type="table-fn"}No.%No.%Age range, month1--1320.07--1560.725Mean ± SD26.17 ± 21.4829.73 ± 24.86 ≤ 186645.5223343.88 \> 187954.4829856.12Gender0.956 Female6444.1423343.88 Male8155.8629856.12Clinical stages I42.76 II4933.79 III5034.48 IV3322.76 NA96.21[^2]

3.2. Association Analysis {#s0040}
-------------------------

We performed the goodness-of-fit *χ*^2^ test to test whether the distribution of genotype frequency of SNPs departed from expected pattern ([Table 2](#t0010){ref-type="table"}). All the *P* values were above 0.05 (rs7585356 G \> A: *P*~HWE~ = 0.948; rs6435862 T \> G: *P*~HWE~ = 0.205; rs3768716 A \> G: *P*~HWE~ = 0.415) suggested that all the analyzed SNPs were in accordance with HWE in the control subjects. Single locus analysis demonstrated that the rs7585356 G \> A polymorphism was significantly associated with an increased risk of nephroblastoma (AA vs. GG: adjusted OR = 1.78, 95% CI = 1.01--3.12). There was no association observed for either the rs6435862 T \> G or the rs3768716 A \> G polymorphism. We next examined the combined effects of risk genotypes. There was a trend showing that the risk of nephroblastoma was increasing with the number of risk genotypes (adjusted OR = 1.26, 95% CI = 1.03--1.53). However, only carriers of three risk genotypes were at significantly higher risk than those without risk genotype (adjusted OR = 2.21, 95% CI = 1.18--4.17). Moreover, when we divided subjects into two groups (0--2 and 3 risk genotypes), we found that subjects with 3 risk genotypes exhibited significantly elevated nephroblastoma risk in comparison to subjects with 0--2 risk genotypes (adjusted OR = 1.72, 95% CI = 1.02--2.89).Table 2Logistic regression analysis of associations between *BARD1* polymorphisms and nephroblastoma risk.Table 2GenotypeCases\
(N = 141)Controls\
(N = 531)*P*[a](#tf0010){ref-type="table-fn"}Crude OR\
(95% CI)*P*Adjusted OR\
(95% CI)[b](#tf0015){ref-type="table-fn"}*P*[b](#tf0015){ref-type="table-fn"}rs7585356 (HWE = 0.948)GG53 (37.59)235 (44.26)1.001.00AG64 (45.39)237 (44.63)1.20 (0.80--1.80)0.3851.20 (0.80--1.81)0.372AA24 (17.02)59 (11.11)**1.80 (1.03--3.16)0.0391.78 (1.01--3.12)0.044**Additive0.1281.31 (1.00--1.71)0.0511.30 (1.00--1.71)0.055Dominant88 (62.41)296 (55.74)0.1531.32 (0.90--1.93)0.1561.32 (0.90--1.93)0.155Recessive117 (82.98)472 (88.89)0.0671.64 (0.98--2.75)0.0601.61 (0.96--2.71)0.070  rs6435862 (HWE = 0.205)TT112 (79.43)381 (71.75)1.001.00TG26 (18.44)133 (25.05)0.67 (0.42--1.06)0.0890.66 (0.41--1.06)0.085GG3 (2.13)17 (3.20)0.60 (0.17--2.09)0.4330.62 (0.18--2.15)0.449Additive0.1710.70 (0.47--1.04)0.0760.70 (0.47--1.04)0.077Dominant29 (20.57)150 (28.25)0.0610.66 (0.42--1.03)0.0680.66 (0.42--1.03)0.067Recessive138 (97.87)514 (96.80)0.4880.66 (0.19--2.28)0.5080.68 (0.20--2.35)0.538  rs3768716 (HWE = 0.415)AA108 (76.60)364 (68.55)1.001.00AG29 (20.57)148 (27.87)0.66 (0.42--1.04)0.0720.65 (0.41--1.03)0.064GG4 (2.84)19 (3.58)0.71 (0.24--2.13)0.5410.73 (0.24--2.19)0.572Additive0.1660.72 (0.50--1.05)0.0870.72 (0.49--1.05)0.083Dominant33 (23.40)167 (31.45)0.0590.67 (0.43--1.03)0.0650.66 (0.43--1.02)0.059Recessive137 (97.16)512 (96.42)0.6600.79 (0.26--2.35)0.6680.81 (0.27--2.42)0.703  Combined effect of risk genotypes027 (19.15)141 (26.55)1.001.0018 (5.67)32 (6.03)1.31 (0.54--3.14)0.5511.27 (0.53--3.07)0.591282 (58.16)302 (56.87)1.42 (0.88--2.29)0.1531.43 (0.88--2.31)0.146324 (17.02)56 (10.55)**2.24 (1.19--4.21)0.0122.21 (1.18--4.17)0.014**Trend0.021**1.26 (1.03--1.53)0.0221.26 (1.03--1.53)0.022**0--2117 (82.98)457 (89.45)1.001.00324 (17.02)56 (10.55)0.042**1.74 (1.04--2.92)0.0371.72 (1.02--2.89)0.042**[^3][^4][^5]

3.3. Stratified Analysis {#s0045}
------------------------

We then performed stratified analysis to explore how age, gender, and clinical stage influence the association between selected polymorphisms and nephroblastoma susceptibility ([Table 3](#t0015){ref-type="table"}). No association was observed between individual SNPs and nephroblastoma susceptibility in subgroups defined by age and sex. Interestingly, we found that subjects carrying rs7585356 AA genotype significantly tended to develop clinical stage I + II nephroblastoma, when compared with those carrying G alleles. However, the rs7585356 AA genotype did not appear to increase the risk of clinical stage III + IV nephroblastoma. We further investigated the cumulative effects of these SNPs on nephroblastoma in the stratified analysis. We found that the presence of three risk genotypes was significantly associated with the risk of nephroblastoma in females when compared with that of 0--2 risk genotypes (adjusted OR = 2.19, 95% CI = 1.01--4.71). Moreover, carriers of three genotypes had 2.29-fold increase in the risk of developing clinical stage I + II nephroblastoma (95% CI = 1.10--4.77).Table 3Stratification analysis for association between *BARD1* genotypes and nephroblastoma risk.Table 3Variablesrs7585356\
(case/control)Adjusted OR[a](#tf0020){ref-type="table-fn"}*P*[a](#tf0020){ref-type="table-fn"}rs6435862\
(case/control)Adjusted OR[a](#tf0020){ref-type="table-fn"}*P*[a](#tf0020){ref-type="table-fn"}rs3768716\
(case/control)Adjusted OR[a](#tf0020){ref-type="table-fn"}*P*[a](#tf0020){ref-type="table-fn"}Risk genotypes\
(case/control)Adjusted OR[a](#tf0020){ref-type="table-fn"}*P*[a](#tf0020){ref-type="table-fn"}GG/AGAA(95% CI)TTTG/GG(95% CI)AAAG/GG(95% CI)0--23(95% CI)Age, month≤ 1856/20512/281.69 (0.81--3.55)0.16549/16715/660.78 (0.41--1.48)0.44747/15417/790.71 (0.38--1.32)0.27752/20612/271.77 (0.84--3.73)0.134\> 1865/26712/311.62 (0.79--3.32)0.19363/21414/840.56 (0.30--1.05)0.07061/21016/880.61 (0.33--1.12)0.11065/26912/291.74 (0.84--3.61)0.134  GenderFemale52/21012/232.08 (0.97--4.46)0.06052/16012/730.51 (0.26--1.01)0.05449/15013/830.55 (0.29--1.05)0.07052/21112/22**2.19 (1.01--4.71)0.046**Male65/26212/361.32 (0.65--2.69)0.44160/22117/770.80 (0.44--1.46)0.47459/21418/840.76 (0.43--1.37)0.36965/26412/341.42 (0.70--2.90)0.335  Clinical stageI + II40/47211/59**2.14 (1.03--4.45)0.041**41/38110/1500.62 (0.30--1.27)0.19041/36410/1670.51 (0.25--1.06)0.07140/47511/56**2.29 (1.10--4.77)0.027**III + IV68/47213/591.53 (0.80--2.95)0.20065/38116/1500.63 (0.35--1.12)0.11662/36419/1670.67 (0.39--1.16)0.15768/47513/561.63 (0.84--3.13)0.147[^6][^7]

Thus, when we performed FPRP analysis, all the significant findings disappeared at the prior probability level of 0.1 and FPRP threshold of 0.2 ([Table 4](#t0020){ref-type="table"}).Table 4False-positive report probability values for the association between *BARD1* genotypes and nephroblastoma susceptibility.Table 4GenotypeCrude OR\
(95% CI)*P*[a](#tf0025){ref-type="table-fn"}Statistical power[b](#tf0030){ref-type="table-fn"}Prior probability0.250.10.010.0010.0001rs7585356 G \> A AA vs. GG1.80 (1.03--3.16)0.0390.3070.2760.5340.9270.9920.999 AA vs. GG/AG Stage I + II2.20 (1.07--4.52)0.0320.1620.3710.6390.9510.9950.999Risk genotypes 3 vs. 02.24 (1.19--4.21)0.0120.1750.1750.3880.8750.9860.999 3 vs. 0--21.74 (1.04--2.92)0.0370.2890.2750.5330.9260.9920.999 Females2.21 (1.03--4.76)0.0420.1610.4400.7020.9630.9961.000 Stage I + II2.33 (1.13--4.80)0.0220.1220.3470.6140.9460.9940.999[^8][^9]

4. Discussion {#s0050}
=============

Genetic factors have been known to contribute to the development of nephroblastoma. However, genetic factors related to nephroblastoma are largely unknown, except for some genetic and epigenetic alterations in *WT1* and the 11p15.5 locus ([@bb0030]). Previous GWAS initially discovered six *BARD1* SNPs significantly associated with high-risk neuroblastoma susceptibility ([@bb0015]). We tested the rs6435862 T \> G, rs3768716 A \> G, and rs7585356 G \> A, because the rs6435862 T \> G and rs3768716 A \> G were the most significant SNPs in that GWAS study, and the last one is positioned in the 3′ UTR region. Another reason why we studied these SNP was due to the importance of BARD1 in cancer. These three SNPs were also chosen for our previous replication study in Southern Chinese population with 201 neuroblastoma patients and 531 controls ([@bb0180]).

In this study, we investigated the roles of three polymorphisms in the *BARD1* gene in modifying nephroblastoma susceptibility in this case-control study with 145 nephroblastoma patients and 531 controls. Among the three SNPs, only the rs7585356 G \> A polymorphism was significantly associated with nephroblastoma susceptibility. Intriguingly, stratified analysis indicated that subjects harboring the rs7585356 A alleles were more likely to have early stage of the disease. The rs7585356 AA homozygotes had a significantly increased risk of nephroblastoma at OR of 1.78. Moreover, these SNP might collectively contribute to the risk. The risk of developing nephroblastoma for subjects with three risk genotypes was significantly higher than those carrying two risk genotypes or less. Moreover, in the stratified analysis, the significant association was observed in female and patients with stage I and II disease. Despite the significant findings in the present study, it is should be noted that our previous study reported that based link disequilibrium (LD), these three SNPs could also secure 10 more polymorphisms, using SNPinfo software (<http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm>) ([@bb0180]). The rs3768716 was in LD with rs17487792, rs17487827, rs17488049, rs2070096, while rs7585356 was in LD with rs6720708, rs12614960, 1374230, 16852600, 1979028, and rs207562. As a result, it remain unclear which SNP exactly modifies the risk of nephroblastoma, rs7585356 or another SNP in high LD with it. Moreover, the underlying mechanism by which the significant SNP alters the expression or function of BARD1 needs to be clarified.

A number of lines of evidence has suggested BARD1 as a tumor suppressor ([@bb0080], [@bb0085]). BRCA1-BARD1 heterodimer plays a crucial role in homologous repair in response to DNA damage ([@bb0145]). The knockout of *Bard1* is lethal in mouse ([@bb0105]). The study of *Bard1* knockout mice demonstrated that BARD1 is indispensible to maintain cell viability and genetic stability ([@bb0105]). Conditional knockout *Bard1* in mammary epithelia cells induced the development of breast cancer, which mimics the human breast cancer phenotype observed in individuals, harboring *BRCA1* mutation ([@bb0130]). Mechanistic studies indicated that the BARD1-BRCA1 heterodimer is also implicated in ubiquitin dependent protein degradation as an E3 ubiquitin ligase ([@bb0045]). Mutations that impaired the E3 ubiquitin ligase activity of the heterodimer predispose to breast and ovarian cancer ([@bb0010], [@bb0045], [@bb0125]).

Moreover, some non-synonymous polymorphisms (e.g., cys557Ser, Arg378Ser, Val507Met, and Pro24Ser) in the *BARD1*gene have been also frequently investigated for their association with cancer susceptibility, and studies mainly involved breast cancer ([@bb0115], [@bb0120], [@bb0140], [@bb0165], [@bb0040], [@bb0025], [@bb0150]), neuroblastoma ([@bb0015], [@bb0020]), and cervical cancer ([@bb0190]). Nonetheless, the associations between these *BARD1* SNPs and cancer susceptibility have been often paradoxical. Some studies supported the associations ([@bb0075]), while others had opposite results ([@bb0100]). The factors that contribute to the inconsistency are, but not limited to differences in genotyping methods, experiment designs (hospital-based design or population-based design), different populations and ethnicities, as well as sample size of studies. Therefore, it is critical that all association studies consider external validity issues and candidly state the populations to which the results can be applied. Several meta-analyses were undertaken to reevaluate such associations ([@bb0025], [@bb0100]). Ding et al. reported a lack of association between *BARD1* Cys557Ser polymorphism and breast cancer risk in a pooled analysis comprising 11,870 cases and 7687 controls in 2011 ([@bb0025]). Liu et al. collected 10 case-control studies in 2015 ([@bb0100]). They found that *BARD1* Val507Met and Pro24Ser polymorphisms were associated with decreased cancer risk independently, but not *BARD1* Arg378Ser ([@bb0100]).

A number of limitations of this study should be noted. First, owing to the extremely low incidence of nephroblastoma, the sample size of this case-control was relatively small. Consequently, statistic power of this study was compromised (statistical power no more than 0.307 for significant findings). The significant findings might be chance observations (FPRP values larger than 0.2 at the prior probability level of 0.1). Second, we concentrated on only three *BARD1* SNPs. *BARD1* gene is highly polymorphic, harboring 4941 SNPs as a minimum (<http://www.ncbi.nlm.nih.gov/projects/SNP>). Other SNPs that potentially affect the expression and function of BARD1 should be investigated in the future. Third, we only included Southern Chinese Children in this study. These findings cannot be generalized from one ethnicity to another before validation study. Fourth, in this retrospective study, some important information (e.g., parental exposures) was not available. Due to differences in genetic backgrounds and environmental exposures among the different ethnicities, these findings should be cross-validated with different populations.

Notwithstanding these limitations, our finding did suggest that the rs7585356 G \> A polymorphism may confer genetic susceptibility to nephroblastoma. The studied SNPs collectively may increase the risk of nephroblastoma. Moreover, these SNPs appear to be related to the clinical stages of this disease. Well-designed, large, multi-center studies are warranted to strengthen these findings.
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